Benralizumab

Accurate fatigue scores are essential for assessing benralizumab's impact on patient-reported outcomes. Accurate patient-reported fatigue scores are necessary to assess the treatment impact of benralizumab. Accurate patient-reported fatigue scores are essential for assessing the impact of benralizumab on patient-reported outcomes. A subset of 67 patients received both omalizumab and benralizumab. In the subgroup receiving both omalizumab and benralizumab, 2 of 67 patients (3.0%) had prior HES-related biologic therapy in the preceding 12 months. The benralizumab treatment arm enrolled 67 of the 133 total trial participants. The corrected baseline median eosinophil count for patients assigned to benralizumab was 1,085.0 cells with a range of 360–5,620. Among the 67 patients receiving both omalizumab and benralizumab, 2 patients (3.0%) had prior HES-related biologic therapy in the preceding 12 months. The corrected baseline median eosinophil count for patients assigned to benralizumab is 1,085.0 cells, with a range of 360–5,620. The corrected article concerns a phase 3 trial comparing benralizumab with placebo for hypereosinophilic syndrome. The corrected phase 3 trial evaluated benr…